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Effect of ProRoot MTA® and 
Biodentine® on osteoclastic 
differentiation and activity of mouse 
bone marrow macrophages
Objectives: This investigation aimed to assess the differentiation inhibitory 
effects of ProRoot MTA® (PMTA) and Biodentine® (BIOD) on osteoclasts 
originated from murine bone marrow macrophages (BMMs) and compare 
these effects with those of alendronate (ALD). Materials and Methods: Mouse 
BMMs were cultured to differentiate into osteoclasts with macrophage colony-
stimulating factor and receptor activator of NF-κB (RANKL), treated with 
lipopolysaccharide. After application with PMTA, BIOD, or ALD, cell toxicities 
were examined using WST-1 assay kit, and RANKL-induced osteoclast 
differentiation and activities were determined by resorption pit formation 
assay and tartrate-resistant acid phosphate (TRAP) staining. The mRNA levels 
of osteoclast activity-related genes were detected with quantitative real time 
polymerase chain reaction. Expressions of molecular signaling pathways were 
assessed by western blot. All data were statistically analyzed with one-way 
ANOVA and Tukey’s post-hoc test (p<0.05). Results: Mouse BMMs applied 
with PMTA, BIOD, or ALD showed highly reduced levels of TRAP-positive 
osteoclasts. The BIOD treated specimens suppressed mRNA expressions of 
cathepsin K, TRAP, and c-Fos. Nonetheless, it showed a lower effect than 
PMTA or ALD applications. Compared with ALD, PMTA and BIOD decreased 
RANKL-mediated phosphorylation of ERK1/2 and IκBα. Conclusions: PMTA and 
BIOD showed the inhibitory effect on osteoclast differentiation and activities 
similar to that of ALD through IκB phosphorylation and suppression of ERK 
signaling pathways.
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Introduction
Root resorption, a complication of Dentistry, 
may occur after dental trauma, surgical procedure, 
orthodontic treatment, or bleaching.1 A large area 
of damaged root surface and continual resorption 
process may result in the loss of teeth. As resorption 
is mediated by osteoclasts/odontoclasts, reducing 
osteoclastic activity is a key to inhibit the progression 
of root resorption. Several studies have reported 
a method to suppress the progression of root 
resorption. In cases of avulsion, or surgical procedure 
of intentional replantation, the application of fluoride, 
dexamethasone, or other solutions is recommended.2,3
Osteoclasts (OCLs) are multinucleated giant 
cells resulted from a hematopoietic monocyte or 
macrophage lineage.4 Odontoclasts are multinucleated 
giant cells involved in the resorption of hard dental 
structures and are similar to OCLs regarding cellular 
origins, characteristics, and function including the 
dissolution of mineralized hard tissues.5,6 In this 
respect, anti-resorptive drugs have been used for 
patients with osteoporosis, e.g. bisphosphonate was 
used to inhibit root resorption.7,8 Bisphosphonates 
are a family of popular anti-resorptive agents. 
A family member, alendronate (ALD), exhibited 
increased anti-resorptive capacity upon the addition 
of nitrogen into the side chain.9 In addition to ALD, 
nitrogen-containing bisphosphonates also include 
zolendronate, risedronate, ibandronate, and others.10 
Local treatment with ALD has been shown to prevent 
root resorption by inhibiting macrophages.11,9
Calcium silicate-containing cements (CSCs) are 
widely applied in endodontic treatments, not only 
as a retrograde filling material, but also for pulp 
capping material, apexification, and re-vascularization 
procedures.12,13 Recent studies have reported 
the calcium silicate-containing mineral trioxide 
aggregate (MTA) inhibits OCL differentiation and bone 
resorption, and possesses good biocompatibility and 
bioactivities to promote healing mechanisms.14,15,11 
Biodentine® (BIOD; Septodont, Saint-Maur-des-
Fossés, France), a novel biocompatible repair and 
dentine-like components to MTA have been used 
since 2011.16 BIOD is considered to be an alternative 
to MTA with comparable outcomes in various clinical 
applications.17,16
This investigation aimed to assess the differentiation 
effects of ProRoot MTA® (PMTA) and BIOD on OCLs 
originated from murine bone marrow macrophages 
(BMMs), and compare these effects with those of ALD. 
As few researches have examined the anti-resorptive 
activity of BIOD, the results of this study may support 
the application of CSCs as a choice of treatment to 
prevent root resorption.
Material and methods
Agent preparation
The two CSCs used in this investigation, BIOD 
and PMTA (PMTA; Dentsply, Tulsa, OK, USA), and 
10-8 mol/L ALD (Santa Cruz Biotechnology Inc., 
Santa Cruz, CA, USA) were prepared as described 
in previous studies.18,19 Briefly, BIOD and PMTA were 
mixed according to their respective manufacturer’s 
instructions and packed into sterilized plastic molds 
(5 mm inner diameter, 2 mm thickness). Once set, 
discs were removed from the molds and sterilized 
with ethylene oxide gas. Two discs of each material 
were then placed into 4 mL of α-Minimum Essential 
Medium (α-MEM; HyClone, Logan, UT, USA) containing 
1% penicillin-streptomycin (Gibco, Grand Island, NY, 
USA) in a glass vial, and incubated at 37°C for 72 h. 
After incubation, conditioned media were collected and 
passed through a 0.22 μm filter.
Cell culture method
Six week-old male ICR mice were obtained from 
Koatech (Pyeongtaek, Korea). Primary mouse bone 
marrow cells (BMCs), obtained by flushing femurs and 
tibia, were cultured in α-MEM containing 10% fetal 
bovine serum (FBS; Gibco, Grand Island, NY, USA), 
and 1% penicillin and streptomycin. After culturing for 
24 h, nonadherent cells were harvested and cultured 
with 30 ng/mL of macrophage colony-stimulating 
factor (M-CSF) to produce BMMs. Next, BMMs were 
cultured to differentiate into OCLs with 30 ng/mL of 
M-CSF and 30 ng/mL of receptor activator of NF-kB 
(RANKL; R&D Systems, Minneapolis, MN, USA) for 
more than 4 days. To promote differentiation, 100 
ng/mL of lipopolysaccharide (LPS, Escherichia coli 
O26:B6; Sigma-Aldrich, St. Louis, MO, USA) was 
added after 48 h of M-CSF/RANKL treatment. BMMs 
without RANKL/LPS ((-)CTL) and BMMs with RANKL/
LPS ((+)CTL), i.e. OCLs, were negative and positive 
controls, respectively. Finally, OCLs were treated with 
BIOD conditioned media, PMTA conditioned media, 
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or media with 10-8 mol/L ALD. All experiments were 
performed with these OCLs.
Cytotoxicity assay
Cell viability was evaluated using an EZ-Cytox cell 
viability assay kit (WST method; DoGenBio, Seoul, 
Korea) according to the company’s instructions. OCLs 
at a density of 2x104 cells/mL were seeded into 96-
well plates containing each agent. At 48 h and 72 h 
after cell-seeding, 10 μL of WST solution was added to 
each well. Cells were then incubated for additional 3 h. 
Before investigating the plate, it was well shaken for 1 
min for a homogeneous color distribution. Then, optical 
density (OD) was measured at a wavelength of 450 
nm using a VersaMax micro-plate reader (Molecular 
Devices, Sunnyvale, CA, USA). Consequently, we could 
calculate the final value using the following formulas: 
total signal − background signal = original signal; 
original signal ÷ control signal = viability.
Tartrate-resistant acid phosphatase (TRAP) 
staining
BMMs were seeded in 96-well plates at a density of 
1x104 cells per well and cultured to differentiate into 
OCLs. After incubation with or without each agent for 
24 h, cells were washed with phosphate buffered saline 
(PBS) and fixed for 10 s with liquid containing citrate, 
acetone, and formaldehyde. Next, cells were stained 
using TRAP kit solution (Sigma, St. Louis, MO, USA) 
for 10 – 20 min. TRAP positive cells appeared dark 
red and were identified according to the presence of 
multiple nuclei (n>3). OCLs were counted in triplicate 
cultures using Image-J software version 1.48 (National 
Institutes of Health, Bethesda, MD, USA) on digital 
images acquired with a Nikon Eclipse (TS100, Tokyo, 
Japan) at 100× magnification.
Resorption pit formation assay
BMMs were seeded in 96-well plates previously 
equipped with dentin slices at a density of 1x104 cells 
per well, and subsequently cultured to differentiate 
into OCLs. After incubation with or without each agent 
for 72 h, cells were flushed twice with PBS and then 
scraped off the dentin slices. Slices were then stained 
with TRAP staining solution. Stained pit formation was 
photographed.
RNA isolation and quantitative real-time PCR 
(qRT-PCR)
After a 24-h treatment with or without each agent, 
total RNA was extracted from cultured cells using a 
RNeasy Plus Mini Kit (Qiagen, Hilden, Germany) and 
analyzed for osteoclastic markers: TRAP, cathepsin 
K (CTSK), c-Fos, and GAPDH. RNA samples (1 μg) 
were reverse-transcribed for cDNA synthesis using a 
Maxime RT PreMix Kit (iNtRON Biotech., Seongnam, 
Korea) according to the manufacturer’s instructions. 
cDNA synthesis was carried out at 45°C for 1 h, and 
then incubated at 95°C for 5 min to stop the enzyme 
reaction. The RT product was diluted with 5–20 μL 
sterile water. Figure 1 listed the sequences of primers 
used for PCR amplification. Data were calibrated to 
GAPDH expression and are shown as the mean ratio 
± SD from triplicate experiments.
Western blot
BMMs were seeded into 6-well plates at a density of 
5x104 cells/ml and induced to differentiate into OCLs 
with or without each agent. Cells were flushed twice 
with PBS and lysed using radioimmunoprecipitation 
assay buffer (Tech and Innovation, BRI-9001, 
Chuncheon, South Korea) with protease inhibitor 
cocktail tablets (Roche, Mannheim, Germany). Cells 
were scraped off and incubated on ice for 10 min. Cell 
debris was sonicated and centrifuged at 20,000 × g 
at 4°C for 20 min, and the supernatant was collected 
for western blot analysis. After electrophoresis using 
a 10% SDS-PAGE gel, proteins were transferred 
to immobilized membranes (Millipore, Darmstadt, 
Germany), and then blocked with 5% non-fat milk 
for 1 h at room temperature. Next, membranes were 
incubated with the following primary antibodies: 
anti-phospho-p44/42 MAPK (Erk1/2) (Thr202/
Tyr204), anti-phospho-IκBα (Ser32/36) (5A5), 
anti-p44/42 MAPK (Erk1/2) (137F5), and anti-IκBα 
(L35A5) (Cell Signaling Technology, Beverly, MA, 
Genes Primer sequences
TRAP (F) 5’- CCAATGCCAAAGAGATCGCC - 3’
(R) 5’- TCTGTGCAGAGACGTTGCCAAG - 3’
CTSK (F) 5’- ATACGTTACTCCAGTCAAGAACCAG - 3’
(R) 5’ - TAATTCTCAGTCACACAGTCCACA - 3’
c-Fos (F) 5’ - GGTGAAGACCGTGTCAGGAG - 3’
(R) 5’ - TATTCCGTTCCCTTCGGATT - 3’
GAPDH (F) 5’ - AAGGTCATCCCAGAGCTGAA - 3’
(R) 5’ - CTGCTTCACCACCTTCTTGA - 3’
F, forward; R, reverse; TRAP, tartrate resistant acid phosphatase; 
CTSK, cathepsin K; GAPDH, glyceraldehyde-3-phosphate 
dehydrogenase
Figure 1- Primer sequences for qRT-PCR analysis
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USA). Subsequently, membranes were probed with 
species-specific horseradish peroxidase-conjugated 
secondary antibodies. Signals were examined using 
an ImageQuant LAS 4000 mini (GE Healthcare Life 
Sciences, Björkgatan, Sweden). Phosphorylation of 
IκB and ERK1/2 was determined by western blotting 
of OCLs at 15 and 30 min. Then, membranes were 
stripped and antibodies against non-phosphorylated 
IκB and ERK1/2 were used as a control.
Statistical analysis
All data were derived from triplicates in each of the 
three independent experiments. Data are presented as 
mean±standard deviation (SD). Data were statistically 
analyzed using one-way analysis of variance followed 
by Tukey’s post-hoc test. Statistical significance 
between groups was set at 5% (P<0.05).
Results
Cytotoxicity assay
Viability of OCLs after exposure to agents for 48 
and 72 h was assessed. WST assays showed the 
cytotoxicity of agents did not affect cell viability 
(Figure 2). Cytotoxicity results showed no significant 
differences in cell viability (P>0.05). However, 
ALD presented relatively high cytotoxicity to BMMs 
compared with CSCs.
TRAP staining
Compared with negative control BMMs, RANKL/
LPS-induced BMMs differentiated into mature TRAP 
positive multinucleated OCLs, which served as a 
positive control. However, numbers of TRAP positive 
OCLs decreased upon treatment with each agent. 
The number of TRAP positive cells was significantly 
higher in the positive control group (P<0.05), while no 
significant differences were observed between OCLs 
Figure 2- Bone marrow macrophages (BMMs) were incubated 
with drug-treated media for 48 h or 72 h, after which the viability 
of cells was assessed using a WST assay. Treatment with 
Biodentine (BIOD), ProRoot MTA (PMTA), or alendronate (ALD) 
resulted in decreased cell viability compared with (+) CTL
Figure 3- Tartrate-resistant acid phosphate (TRAP) staining of osteoclasts (OCLs) treated with or without CSCs or ALD. (a) Representative 
images of each group. (-) CTL, BMMs without RANKL/LPS treatment; (+) CTL, OCLs (BMMs treated with RANKL/LPS); BIOD, OCLs 
treated with Biodentine conditioned media; PMTA, OCLs treated with ProRoot MTA conditioned media; ALD, OCLs treated with alendronate. 
(b) Quantification of TRAP-positive osteoclasts. Number of TRAP-positive cells was significantly higher in (+) CTL (P<0.05), while no 
significant differences were observed between BIOD, PMTA, and ALD (P>0.05). Different asterisks (* and **) means that they were 
significantly different each other. BMMs=bone marrow macrophages; CSCs=calcium silicate-based cements; LPS=lipopolysaccharide; 
OCLs=osteoclasts; RANKL=receptor activator of NF-κB; TRAP=tartrate-resistant acid phosphate
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treated with agents (P>0.05) (Figure 3). BIOD showed 
the least TRAP-positive cells, although no statistical 
significance was observed. Thus, CSC treatment 
inhibited RANKL/LPS-induced differentiation of BMMs 
into OCLs at a level similar to ALD.
qRT-PCR
To further examine changes in the differentiation 
of RANKL/LPS-mediated OCLs induced by CSCs, the 
expression of osteoclastogenesis-related genes was 
determined by qRT-PCR (Figure 4). mRNA expression 
of osteoclastic markers decreased in OCLs treated with 
CSCs compared with the positive control (P<0.05), 
demonstrating that the agents used in this study 
affect osteoclastic differentiation of OCLs. Compared 
with BIOD, PMTA showed a similar tendency to ALD 
regarding significantly down-regulated expression of 
TRAP, CTSK, and c-Fos (P<0.05).
Resorption pit assay
To determine whether CSC treatment affected the 
activity of OCLs, the resorption area was examined. 
After 3 days incubation on the dentin disc, mature 
OCLs showed stained pits with purple color (Figure 5). 
CSCs and ALD inhibited the function of mature OCLs, 
as indicated by fewer pits on the discs.
Figure 4- CSCs and ALD exhibited an inhibitory effect on osteoclast differentiation and function. (A) mRNA expression of osteoclastic 
markers TRAP, CTSK, and c-Fos were analyzed by qRT-PCR. mRNA expression of osteoclastic markers was decreased in BIOD, 
PMTA, and ALD compared with (+) CTL (P<0.05). Different asterisks (* and **) means that they showed significantly different each other. 
ALD=alendronate; BIOD=Biodentine; CSCs=calcium silicate-based cements; CTSK=cathepsin K; PMTA=ProRoot MTA; TRAP=tartrate-
resistant acid phosphate
Figure 5- Resorptive activity of OCLs treated with or without CSCs or ALD. CSCs and ALD showed an inhibitory effect on osteoclast 
function. Pit formation was confirmed as something purple on the smooth disc. ALD=alendronate; BIOD=Biodentine; CSCs=calcium 
silicate-based cements; OCLs=osteoclasts; PMTA=ProRoot MTA
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Western blot analysis
To investigate the activation of NF-kB that 
drives RANKL-mediated osteoclastogenesis, IκBα 
phosphorylation was assessed by western blotting 
(Figure 6). CSCs and ALD treatment decreased 
IκBα phosphorylation in OCLs. MAPK activities were 
examined by assessing ERK1/2 phosphorylation 15 and 
30 min after treatment. CSCs and ALD also significantly 
inhibited RANKL-mediated phosphorylation of ERK1/2.
Discussion
Root resorption is mainly caused by OCLs (i.e. 
odontoclasts). ALD, a nitrogenous bisphosphonate, 
is an effective anti-resorptive drug for inhibiting 
OCL activity. Many studies have demonstrated 
the utility of ALD for preventing root resorption of 
replanted avulsed teeth or inhibiting inflammatory 
bone resorption.7,8,20 We also demonstrated that 
ALD treatment inhibited osteoclastic activity in OCLs 
derived from mouse BMMs, consistent with previous 
studies. Nevertheless, it was reported that amino-
containing bisphosphonates, such as alendronic acid, 
possess pro-inflammatory properties that can trigger 
the production of pro-inflammatory cytokines and 
initiate acute-phase inflammation.21,22 Putranto, et al.23 
(2008) reported that ALD transiently increased root pit 
formation because of increased odontoclast numbers.
CSCs, including the first-developed ProRoot 
MTA®, are materials widely applied in Dentistry 
and have the advantage of osteoinductivity. In 
addition, recent studies have reported that CSCs 
prevent osteoclastogenesis and bone resorption to 
enhance bone remodeling, suggesting that silicate 
may take part in the inhibitory behavior of CSCs on 
osteoclastogenesis.24,14 CSCs show varying degrees 
of bioactivity depending on their composition, which 
may affect the ion-releasing property of a material. 
In this regard, it was recently reported the amount 
of silicate dissolution could be larger in BIOD than in 
MTA, as more substantial uptake of calcium and silicate 
by adjacent bovine dentine has been shown.25 Lately, 
an in vivo study reported osteoinductive potential, 
bone bonding ability and biomineralization of newly 
developed CSCs, including BIOD.26 BIOD showed 
osteoinductive properties presenting replacement by 
novel bone. Nonetheless, the inhibitory effect of this 
newly developed bioceramic on osteoclastic activity 
was still obscure. Therefore, we aimed to compare 
the effect of BIOD on osteoclastic activity with PMTA 
and ALD using murine BMMs, and hypothesized that 
CSCs such as BIOD could be considered an alternative 
to ALD for inhibition of root resorption.
RANKL, a component of the tumor necrosis factor 
superfamily expressed by the stromal environment, 
binds to its functional receptor, RANK, on OCLs to 
induce osteoclastogenesis. Indeed, RANKL/RANK 
signaling plays a crucial role in OCL differentiation, 
activation, and survival.27,28 LPS, a composition 
of Gram-negative bacterial cell walls, is a famous 
pathogen of inflammatory bone resorption. LPS 
Figure 6- CSCs and ALD suppressed activation of the NF-kB pathway in RANKL/LPS-stimulated BMMs. ALD=alendronate; BIOD=Biodentine; 
BMMs=bone marrow macrophages; CSCs=calcium silicate-based cements; LPS=lipopolysaccharide; OCLs=osteoclasts; PMTA=ProRoot 
MTA; RANKL=receptor activator of NF-κB
Effect of ProRoot MTA® and Biodentine® on osteoclastic differentiation and activity of mouse bone marrow macrophages
J Appl Oral Sci. 2019;27:e201801507/8
reportedly stimulates the survival and fusion of OCL 
progenitors independent of RANKL,29 and reportedly 
induces OCL formation.30 Most root resorptions 
involve in the inflammatory environment of pulp 
and/or periapical tissue. Therefore, we treated BMMs 
sequentially with M-CSF, RANKL, and LPS to form OCLs 
in this study.
In accordance with a previous study,19 neither 
CSCs nor cements containing antiosteoporotic drugs 
were cytotoxic to BMMs and OCLs, as evaluated by 
WST assay. Given that local treatment of ALD can 
compromise the revascularization of the alveolus 
around the replanted teeth after avulsion,9 non-
toxic concentrations (≤10−8 mol L-1) were applied to 
determine the effects of ALD on osteoclastogenesis 
using RAW cells. However, BMMs used in this study are 
known to be more sensitive than RAW cells, yielding 
higher cytotoxicity compared with the results of 
previous studies, even without statistical differences. 
In addition, previous studies have reported that BIOD 
and PMTA have similar properties concerning effects 
on cell viability.31,32 This agrees with the findings of this 
study, which showed BIOD and PMTA had comparable 
effects on osteoblast cell biocompatibility.
In this study, OCLs derived from BMMs were 
confirmed to express active TRAP enzyme, a key 
marker involved in osteoclastic bone resorption. These 
TRAP positive vesicles may represent a prominent 
biosynthetic vesicular trafficking route for OCLs to 
target new synthetic proteins to the ruffled borders.33 
In OCLs, the enzyme, TRAP, which is specifically 
expressed, can be used as a marker to detect activated 
multinucleated OCLs. The results of this study showed 
TRAP positive multinucleated OCLs were induced at 
the highest rate in positive controls that matched the 
previous results.34,35 Meanwhile, negative controls did 
not yield TRAP-positive OCLs (Figure 3). Compared 
with the positive control, CSCs and ALD reduced the 
accretion of a prominent pool of TRAP positive vesicles; 
however, there was no significant difference among 
the three treatments (Figure 3).
OCL differentiation is related to the expression 
of genes encoding TRAP, CTSK, c-Fos, and other 
factors.36 CTSK is highly expressed in OCLs and plays 
an important role in bone resorption.35 OCLs derived 
from BMMs exhibit the essential characteristics of 
OCLs formed in vivo, most notably, TRAP and CTSK 
expression.37 The results of mRNA analysis in this 
study showed PMTA and ALD decreased RANKL/
LPS-induced OCL differentiation, consistent with 
previous studies.16,9,19,38 BIOD also inhibited the mRNA 
expression of osteoclastic markers, but to a lesser 
extent than PMTA or ALD (P<0.05, Figure 4).
To further delineate the immediate effects 
of signaling pathways for RANKL/LPS-induced 
osteoclastogenesis, phosphorylation of IκBα and 
ERK1/2 was assessed. RANKL interacts with the OCL 
surface receptor RANK, which recruits tumor necrosis 
factor receptor-associated factor 6 (TRAF6) to further 
activate various downstream signaling pathways 
such as nuclear factor-κB (NF-κB) and three mitogen 
activated protein kinases (MAPKs) including p38 
MAPK, ERK1/2, and c-jun N-terminal kinase.39 NF-κB is 
inactive in the cytosol because it is bound to IκBα, but 
becomes active once IκBα has been phosphorylated. 
According to these results, phosphorylation of 
ERK1/2 was significantly inhibited by CSCs or ALD, 
suggesting CSCs targeted the MAPK cascade (Figure 
6). NF-κB signaling is also downregulated, although 
phosphorylation of IκBα seemed to be less inhibited 
compared with ERK1/2. These results suggest 
downregulation of MAPKs and NF-κB signaling is 
a mechanism involved in the antiosteoclastogenic 
activity of CSCs and ALD.
Conclusions
Within the limitations of this study, we conclude 
that BIOD and PMTA show an inhibitory effect on OCL 
differentiation and function similar to alendronate 
via inhibition of ERK signaling pathways and IκB 
phosphorylation. The explanation of the precise 
mechanisms underlying the effect of CSCs and their 
direct relationship with adjacent tissues over a longer 
period of time requires further in vitro and in vivo 
studies.
Acknowledgement
The authors declare no conflicts of interest related 
to this study. This work was supported by a National 
Research Foundation of Korea (NRF) grant funded by 
the Korea government (2015R1C1A2A01054748 and 
2017R1D1A3B03031966).
KIM M, KIM S, KO H, SONG M
J Appl Oral Sci. 2019;27:e201801508/8
References
1- Fuss Z, Tsesis I, Lin S. Root resorption - diagnosis, classification 
and treatment choices based on stimulation factors. Dent Traumatol. 
2003;19(4):175-82.
2- Andersson L, Andreasen JO, Day P, Heithersay G, Trope M, Diangelis 
AJ, et al. International Association of Dental Traumatology guidelines for 
the management of traumatic dental injuries: 2. Avulsion of permanent 
teeth. Dent Traumatol. 2012;28(2):88-96.
3- Kum KY, Kwon OT, Spängberg LS, Kim CK, Kim J, Cho MI, et al. Effect 
of dexamethasone on root resorption after delayed replantation of rat 
tooth. J Endod. 2003;29(12):810-3.
4- Jiang J, Li H, Fahid FS, Filbert E, Safavi KE, Spangberg LS, et al. 
Quantitative analysis of osteoclast-specific gene markers stimulated by 
lipopolysaccharide. J Endod. 2006;32(8):742-6.
5- Arana-Chavez VE, Bradaschia-Correa V. Clastic cells: mineralized 
tissue resorption in health and disease. Int J Biochem Cell Biol. 
2009;41(3):446-50.
6- Sahara N, Ashizawa Y, Nakamura K, Deguchi T, Suzuki K. 
Ultrastructural features of odontoclasts that resorb enamel in human 
deciduous teeth prior to shedding. Anat Rec. 1998;252(2):215-28.
7- Choi SC, Kwon YD, Kim KC, Kim GT. The effects of topical application 
of bisphosphonates on replanted rat molars. Dent Traumatol. 
2010;26(6):476-80.
8- Levin L, Bryson EC, Caplan D, Trope M. Effect of topical alendronate 
on root resorption of dried replanted dog teeth. Dent Traumatol. 
2001;17(3):120-6.
9- Martins CA, Leyhausen G, Volk J, Geurtsen W. Effects of alendronate 
on osteoclast formation and activity in vitro. J Endod. 2015;41(1):45-9.
10- Otto S, Pautke C, Opelz C, Westphal I, Drosse I, Schwager J, 
et al. Osteonecrosis of the jaw: effect of bisphosphonate type, local 
concentration, and acidic milieu on the pathomechanism. J Oral 
Maxillofac Surg. 2010;68(11):2837-45.
11- Kim S, Kratchman S. Modern endodontic surgery concepts and 
practice: a review. J Endod. 2006;32(7):601-23.
12- Nosrat A, Seifi A, Asgary S. Regenerative endodontic treatment 
(revascularization) for necrotic immature permanent molars: a 
review and report of two cases with a new biomaterial. J Endod. 
2011;37(4):562-7.
13- Parirokh M, Torabinejad M. Mineral trioxide aggregate: a 
comprehensive literature review - Part III: Clinical applications, 
drawbacks, and mechanism of action. J Endod. 2010;36(3):400-13.
14- Hashiguchi D, Fukushima H, Yasuda H, Masuda W, Tomikawa M, 
Morikawa K, et al. Mineral trioxide aggregate inhibits osteoclastic bone 
resorption. J Dent Res. 2011;90(7):912-7.
15- Hung CJ, Kao CT, Chen YJ, Shie MY, Huang TH. Antiosteoclastogenic 
activity of silicate-based materials antagonizing receptor activator for 
nuclear factor kappaB ligand-induced osteoclast differentiation of murine 
marcophages. J Endod. 2013;39(12):1557-61.
16- Malkondu O, Karapinar Kazandağ M, Kazazoğlu E. A review on 
biodentine, a contemporary dentine replacement and repair material. 
Biomed Res Int. 2014;2014:160951.
17- Katge FA, Patil DP. Comparative analysis of 2 calcium silicate-
based cements (Biodentine and mineral trioxide aggregate) as direct 
pulp-capping agent in young permanent molars: a split mouth study. 
J Endod. 2017;43(8):507-13.
18- Kim M, Yang W, Kim H, Ko H. Comparison of the biological properties 
of ProRoot MTA, OrthoMTA, and Endocem MTA cements. J Endod. 
2014;40(10):1649-53.
19- Yang W, Ko H, Kim H, Kim M. The effect of cathepsin K inhibitor 
on osteoclastic activity compared to alendronate and enamel matrix 
protein. Dent Traumatol. 2015;31(3):202-8.
20- Komatsu K, Shimada A, Shibata T, Shimoda S, Oida S, Kawasaki 
K, et al. Long-term effects of local pretreatment with alendronate on 
healing of replanted rat teeth. J Periodontal Res. 2008;43(2):194-200.
21- Coxon FP, Thompson K, Rogers MJ. Recent advances in 
understanding the mechanism of action of bisphosphonates. Curr Opin 
Pharmacol. 2006;6(3):307-12.
22- Dicuonzo G, Vincenzi B, Santini D, Avvisati G, Rocci L, Battistoni 
F, et al. Fever after zoledronic acid administration is due to increase in 
TNF-alpha and IL-6. J Interferon Cytokine Res. 2003;23(11):649-54.
23- Putranto R, Oba Y, Kaneko K, Shioyasono A, Moriyama K. Effects 
of bisphosphonates on root resorption and cytokine expression during 
experimental tooth movement in rats. Orthod Waves. 2008;67(4):141-
9.
24- Cheng X, Zhu L, Zhang J, Yu J, Liu S, Lv F, et al. Anti-
osteoclastogenesis of Mineral Trioxide Aggregate through Inhibition of 
the Autophagic Pathway. J Endod. 2017;43(5):766-73.
25- Han L, Okiji T. Uptake of calcium and silicon released from calcium 
silicate-based endodontic materials into root canal dentine. Int Endod 
J. 2011;44(12):1081-7.
26- Gandolfi MG, Iezzi G, Piattelli A, Prati C, Scarano A. Osteoinductive 
potential and bone-bonding ability of ProRoot MTA, MTA Plus and 
Biodentine in rabbit intramedullary model: microchemical characterization 
and histological analysis. Dent Mater. 2017;33(5):e221-38.
27- Odgren PR, Kim N, MacKay CA, Mason-Savas A, Choi Y, Marks SC 
Jr. The role of RANKL (TRANCE/TNFSF11), a tumor necrosis factor 
family member, in skeletal development: effects of gene knockout 
and transgenic rescue. Connect Tissue Res. 2003;44 Suppl 1:264-71.
28- Pettit AR, Ji H, von Stechow D, Müller R, Goldring SR, Choi Y, et al. 
TRANCE/RANKL knockout mice are protected from bone erosion in a 
serum transfer model of arthritis. Am J Pathol. 2001;159(5):1689-99.
29- Toyomura T, Murata Y, Yamamoto A, Oka T, Sun-Wada GH, Wada Y, 
et al. From lysosomes to the plasma membrane: localization of vacuolar-
type H+ -ATPase with the a3 isoform during osteoclast differentiation. 
J Biol Chem. 2003;278(24):22023-30.
30- Islam S, Hassan F, Tumurkhuu G, Dagvadorj J, Koide N, Naiki Y, et al. 
Bacterial lipopolysaccharide induces osteoclast formation in RAW 264.7 
macrophage cells. Biochem Biophys Res Commun. 2007;360(2):346-51.
31- Attik GN, Villat C, Hallay F, Pradelle-Plasse N, Bonnet H, Moreau 
K, et al. In vitro biocompatibility of a dentine substitute cement on 
human MG63 osteoblasts cells: Biodentine™ versus MTA(®). Int Endod 
J. 2014;47(12):1133-41.
32- Daltoé MO, Paula-Silva FW, Faccioli LH, Gatón-Hernández PM, De 
Rossi A, Bezerra Silva LA. Expression of mineralization markers during 
pulp response to Biodentine and mineral trioxide aggregate. J Endod. 
2016;42(4):596-603.
33- Palokangas H, Mulari M, Väänänen HK. Endocytic pathway from 
the basal plasma membrane to the ruffled border membrane in bone-
resorbing osteoclasts. J Cell Sci. 1997;110(Pt 15):1767-80.
34- Hao L, Chen W, McConnell M, Zhu Z, Li S, Reddy M, et al. A small 
molecule, odanacatib, inhibits inflammation and bone loss caused by 
endodontic disease. Infect Immun. 2015;83(4):1235-45.
35- Suzuki N, Takimoto K, Kawashima N. Cathepsin K inhibitor regulates 
inflammation and bone destruction in experimentally induced rat 
periapical lesions. J Endod. 2015;41(9):1474-9.
36- Zaidi M, Blair HC, Moonga BS, Abe E, Huang CL. Osteoclastogenesis, 
bone resorption, and osteoclast-based therapeutics. J Bone Miner Res. 
2003;18(4):599-609.
37- Collin-Osdoby P, Yu X, Zheng H, Osdoby P. RANKL-mediated 
osteoclast formation from murine RAW 264.7 cells. Methods Mol Med. 
2003;80:153-66.
38- Zhang J, Zhu L, Yan P, Peng B. Effect of BioAggregate on receptor 
activator of nuclear factor-kappa B ligand-induced osteoclastogenesis 
from murine macrophage cell line in vitro. J Endod. 2015;41(8):1265-
71.
39- Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin 
TJ. Modulation of osteoclast differentiation and function by the new 
members of the tumor necrosis factor receptor and ligand families. 
Endocr Rev. 1999;20(3):345-57.
Effect of ProRoot MTA® and Biodentine® on osteoclastic differentiation and activity of mouse bone marrow macrophages
